Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying ...
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying ...
Think of the bone marrow as the body’s factory for blood and immune cells. In myelodysplastic syndromes (MDS), that factory breaks down—producing too few cells, and the ones that do roll off the line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results